Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva

This is an open-label, single arm, phase 2 study designed to evaluate the efficacy of tisotumab vedotin in participants with recurrent or metastatic squamous cell carcinoma of the vulva by estimating the objective response rate. Patients will receive tisotumab vedotin every 3 weeks (21 days plus or minus 3 days). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.

NCT Number	NCT07672782
Lead Sponsor	GOG Foundation Collaborators: Pfizer
Conditions	Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva
Enrollment	28 participants
Start Date	2026-11
Primary Completion	2029-03 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-29